查看購物車
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1997393

新生兒篩檢市場：依技術、檢測類型、檢體類型和最終用戶分類－2026-2032年全球市場預測

Newborn Screening Market by Technology, Test Type, Sample Type, End User - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 199 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2025 年，新生兒篩檢市場價值將達到 9.8243 億美元，到 2026 年將成長至 10.7232 億美元，到 2032 年將達到 19.9738 億美元，年複合成長率為 10.66%。

主要市場統計數據
基準年 2025 9.8243億美元
預計年份：2026年 1,072,320,000 美元
預測年份 2032 1,997,380,000 美元
複合年成長率 (%) 10.66%

對技術融合、臨床重點和營運限制如何重塑新生兒篩檢計畫進行全面的背景概述。

新生兒篩檢在兒童預防醫學中發揮著至關重要的作用，它能夠早期發現可能導致終身嚴重後果的先天性疾病。近年來，診斷方法已從單一參數檢測發展到利用多參數檢測平台和基因組分析的工作流程，這迫使臨床醫生、實驗室技術人員和政策制定者重新思考篩檢路徑和基礎設施。因此，相關人員必須在臨床敏感性和特異性與操作可行性、檢體管理以及不斷成長的基因組數據相關的倫理考量之間取得平衡。

對正在重新定義新生兒篩檢服務模式的技術、資料管治和相關人員合作方面的廣泛轉變進行策略分析。

新生兒篩檢領域正經歷一場變革，主要得益於分析平台、生物資訊學以及相關人員期望的快速發展。高解析度技術，例​​如串聯式質譜質譜和次世代定序，拓展了診斷能力，使得過去常規檢測難以發現的代謝和遺傳性疾病得以早期發現。同時，免疫檢測靈敏度的提高和分子檢測技術的進步縮短了結果報告時間，並最佳化了確診流程，使篩檢結果在新生兒護理中更具實用價值。

對近期關稅變化和貿易政策轉變如何影響新生兒篩檢的供應連續性、籌資策略和營運韌性進行基於證據的評估。

全球貿易環境中的政策調整和關稅措施可能會對整個新生兒篩檢系統產生連鎖反應，影響診斷設備、耗材和試劑的供應和成本結構。進口關稅的提高可能導致檢查室和醫療機構的採購週期延長、單位成本上升，對其營運預算和籌資策略造成壓力。為此，一些機構可能會優先考慮供應商多元化、尋找本地生產合作夥伴或重新協商服務契約，以維持檢測服務的連續性。

以細分為主導的綜合分析，解釋了技術選擇、測試組合、最終用戶工作流程和檢體模式如何相互作用，從而確定實施路徑和操作設計。

細分市場洞察揭示了臨床需求、技術能力和終端使用者工作流程的交集，從而塑造了產品開發和服務交付的策略重點。在各種技術模式中，高效液相層析(HPLC) 持續發揮獨特的分析作用，而免疫檢測平台則可實現蛋白質生物標記的高通量篩檢。包括聚合酵素鏈鎖反應(PCR) 和桑格定序在內的分子技術能夠實現標靶且快速的基因鑑定。次世代定序(NGS) 可建構更廣泛的基因組panel並應用於藥物發現。串聯式質譜質譜仍然是多參數代謝篩檢的核心。綜上所述，這些技術構成了一個多層次的診斷架構，其中快速且低成本的篩檢可引導使用者進行一系列更具特異性的分子或基因組確認檢測。

從本地觀點探討區域政策、基礎設施成熟度和供應鏈本地化如何影響新生兒篩檢計畫的設計和永續性。

區域趨勢對新生兒篩檢計畫的設計、監管預期和供應鏈韌性有顯著影響。在美洲，公共衛生計畫通常強調標準化篩檢方案，並輔以集中式檢查室網路和公私混合醫療服務模式，從而促進規模經濟和大量籌資策略。政策和投資的轉型轉變促使人們對更多基因組相關檢測和試驗計畫產生興趣，但相關人員必須在擴大篩選範圍的同時兼顧公平性和後續照護基礎設施。

策略性地整合以互通性、證據產生、策略夥伴關係和卓越服務為重點的競爭行動，以推動新生兒篩檢供應商的市場格局。

產業參與者之間的競爭動態呈現出技術差異化、策略夥伴關係以及專注於服務和支援以滿足臨床和檢查室需求的趨勢。領先的儀器製造商致力於透過工作流程自動化增強平台互通性並縮短結果出具時間，而試劑供應商則優先考慮批間一致性和符合法規要求的文檔，以支援認證要求。同時，實驗室服務供應商和參考網路致力於擴展其確診檢測能力並制定標準化診療路徑，以最大限度地縮短從診斷到開始治療的時間。

領導者必須應對的策略挑戰，才能將篩檢的進步轉化為臨床成果：加速部署、確保供應彈性、建立品質架構。

產業領導者需要採取行動，將技術潛力轉化為營運和臨床成果，同時應對複雜的政策和供應鏈問題。首先，應投資於可互通的檢查室資訊系統和標準化報告格式，以確保篩檢結果無縫整合到電子健康記錄和人群健康登記系統中，從而增強後續工作的連續性和結果評估的準確性。其次，應優先發展人力資源，透過資助實務培訓、遠端支援和能力評估，確保檢查室和臨床醫生能夠應用不斷發展的檢測方法並解讀複雜的基因檢測觀察。

透過文獻整合、專家對話和迭代檢驗，我們透過透明、多方面的調查方法，確保對新生兒篩檢提供穩健且實用的見解。

本研究途徑結合了系統性的二手文獻綜述、與領域專家的有針對性的一手訪談以及嚴謹的資料三角驗證，從而確保研究結果的有效性和實用性。首先，調查方法整合了同行評審文獻、監管指導文件、技術白皮書和會議論文集，以了解當前的技術現狀、臨床指南和操作實踐。這為識別關鍵主題和知識缺口奠定了基礎，這些主題和缺口需要透過一手研究進行深入探討。

簡潔扼要的總結強調，需要協調技術創新、營運基礎設施和公平的專案設計，以最大限度地發揮新生兒篩檢的益處。

總之，新生兒篩檢正處於轉折點，分析技術、數據整合和策略合作的創新有望顯著提高兒童的早期檢出率和長期預後。從串聯式質譜質譜和高效液相層析到標靶分子檢測和全基因測序，各項技術進步提供了互補的功能，可供檢查室和醫療系統在逐步篩檢流程中加以利用。然而，要真正實現臨床獲益，營運框架、監管合規性以及跨地區和醫療機構的公平取得至關重要。

目錄

第1章：序言

第2章：調查方法

  • 調查設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查的前提
  • 研究限制

第3章執行摘要

  • 首席體驗長觀點
  • 市場規模和成長趨勢
  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 波特五力分析
  • PESTEL 分析
  • 市場展望
  • 上市策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

第8章：新生兒篩檢市場：依技術分類

  • 高效液相層析
  • 免疫檢測
  • 分子技術
    • 聚合酵素鏈鎖反應
    • 桑格法
  • 次世代定序
  • 串聯式質譜質譜法

第9章：新生兒篩檢市場（依檢測類型分類）

  • 囊腫纖維化
  • 內分泌疾病
  • 血紅素異常
  • 先天性代謝缺陷

第10章新生兒篩檢市場（檢體類型分類）

  • 乾血斑
  • 血清檢體

第11章：新生兒篩檢市場：依最終用戶分類

  • 診斷檢查室
  • 醫院和診所
  • 研究所

第12章：新生兒篩檢市場：按地區分類

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第13章：新生兒篩檢市場：依組別分類

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第14章：新生兒篩檢市場：依國家分類

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第15章：美國新生兒篩檢市場

第16章：中國新生兒篩檢市場

第17章 競爭格局

  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年
  • Abbott Laboratories
  • Agilent Technologies, Inc.
  • Bio-Rad Laboratories, Inc.
  • BioMerieux SA
  • Danaher Corporation
  • MP Biomedicals LLC
  • Novartis AG
  • PerkinElmer, Inc.
  • Shimadzu Corporation
  • Siemens Healthineers AG
  • Thermo Fisher Scientific Inc.
  • Trivitron Healthcare
  • Waters Corporation
Product Code: MRR-501246436EC1

The Newborn Screening Market was valued at USD 982.43 million in 2025 and is projected to grow to USD 1,072.32 million in 2026, with a CAGR of 10.66%, reaching USD 1,997.38 million by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 982.43 million
Estimated Year [2026] USD 1,072.32 million
Forecast Year [2032] USD 1,997.38 million
CAGR (%) 10.66%

A definitive contextual overview of how technological convergence, clinical priorities, and operational constraints are reshaping newborn screening programs

Newborn screening occupies a pivotal role in preventive pediatric healthcare by enabling early detection of congenital conditions that can profoundly affect lifelong outcomes. Over recent years, the diagnostic landscape has evolved from single-analyte assays toward multiplexed platforms and genomics-enabled workflows, prompting clinicians, laboratorians, and policy makers to reassess screening pathways and infrastructure. Consequently, stakeholders must balance clinical sensitivity and specificity with operational feasibility, sample logistics, and ethical considerations surrounding expanded genomic data.

As technology converges with clinical practice, laboratory networks and end users face novel integration challenges. Dried blood spot specimens remain foundational for many programs, yet serum-based assays and molecular workflows now complement and sometimes supplant traditional approaches. This shift has practical implications for specimen collection, cold chain management where applicable, and the downstream analytics that inform diagnostic confirmation and therapeutic interventions.

Moreover, regulatory expectations and payer scrutiny increasingly emphasize outcomes and cost-effectiveness, driving demand for robust evidence generation and standardized quality frameworks. Therefore, health systems and suppliers must collaborate to optimize protocols, training, and data capture to ensure reliable population-level screening while preserving patient privacy and informed consent. Ultimately, a strategic introduction to the current state of newborn screening highlights the interplay of science, policy, and operational execution that will define next-generation programs

A strategic analysis of the sweeping technological, data governance, and stakeholder collaboration shifts that are redefining newborn screening delivery models

The newborn screening landscape is undergoing transformative shifts driven by rapid advances in analytical platforms, bioinformatics, and stakeholder expectations. High-resolution techniques such as tandem mass spectrometry and next-generation sequencing have expanded diagnostic breadth, enabling earlier identification of metabolic and genetic disorders that previously eluded routine detection. At the same time, improvements in immunoassay sensitivity and molecular assays have reduced turnaround times and improved confirmatory workflows, making screening results more actionable in neonatal care settings.

Concurrently, the integration of digital health tools and laboratory information systems has elevated data management, facilitating automated flagging, longitudinal tracking, and tighter linkage between screening and follow-up care. These developments are accompanied by increasing emphasis on harmonized quality metrics and proficiency testing, which together reinforce trust in expanded screening panels. Moreover, public health authorities and clinical networks are revisiting screening panels and consent models to accommodate genomic findings while managing ethical implications.

Finally, the rise of collaborative partnerships across instrument manufacturers, reagent suppliers, clinical laboratories, and payers supports innovation diffusion and scale-up. As a result, organizations that prioritize interoperability, scalable workflows, and clinician engagement will navigate this transformation most effectively, positioning themselves to translate technical capability into improved neonatal outcomes

An evidence-based appraisal of how recent tariff shifts and trade policy changes can influence supply continuity, procurement strategies, and operational resilience in newborn screening

Policy adjustments and tariff measures introduced in global trade environments can ripple through the newborn screening ecosystem by affecting the availability and cost structure of diagnostic instruments, consumables, and reagents. When import tariffs rise, laboratories and healthcare providers may confront longer procurement cycles and elevated unit costs for capital equipment and single-use kits, which in turn can pressure operational budgets and procurement strategies. In response, some organizations may prioritize supplier diversification, seek localized manufacturing partners, or renegotiate service contracts to preserve continuity of testing services.

At the same time, higher input costs can accelerate adoption of maintenance and lifecycle management practices that extend equipment usability and reduce downtime. For example, laboratories may intensify preventive maintenance scheduling, invest in training that broadens in-house technical capabilities, and adopt standardized consumables across testing platforms to achieve economies of scale. Additionally, procurement teams may increase emphasis on total cost of ownership analyses and multi-year supply agreements to buffer against tariff volatility.

Importantly, regulatory compliance and quality assurance requirements will continue to shape supplier selection regardless of tariff dynamics. Therefore, while policymakers and industry participants adapt to evolving trade conditions, the primary focus remains on preserving diagnostic accuracy, turnaround time, and equitable access to newborn screening. In the longer term, shifts in trade policy may incentivize reshoring of certain manufacturing capabilities and foster regional supply ecosystems that enhance resilience without compromising clinical standards

A cohesive segmentation-driven analysis explaining how technology choices, test portfolios, end-user workflows, and specimen modalities interact to determine adoption pathways and operational design

Insight into segmentation illuminates where clinical need, technological capability, and end-user workflows intersect, shaping strategic priorities for product development and service delivery. Across technology modalities, High Performance Liquid Chromatography continues to serve niche analytical roles while Immunoassay platforms provide high-throughput screening for protein biomarkers; Molecular Techniques comprising Polymerase Chain Reaction and Sanger Sequencing deliver targeted, rapid genetic confirmation; Next Generation Sequencing enables broader genomic panels and discovery applications; and Tandem Mass Spectrometry remains central for multiplex metabolic screening. Taken together, these platforms create a layered diagnostic architecture where rapid, low-cost screens feed into more specific molecular or genomic confirmatory pipelines.

Regarding test types, traditional screens for conditions such as cystic fibrosis, endocrine disorders, hemoglobinopathies, and inborn errors of metabolism maintain high clinical urgency and established care pathways. These test categories influence assay validation requirements, specimen handling protocols, and clinical follow-up algorithms. In parallel, end users across diagnostic laboratories, hospitals and clinics, and research laboratories have distinct priorities: diagnostic laboratories emphasize throughput, accreditation, and cost control; hospitals and clinics focus on clinical integration and timely result reporting; and research laboratories prioritize assay flexibility and data richness for translational studies.

Sample type considerations further shape operational design, as dried blood spot specimens support broad population screening with logistical simplicity and archival stability, while serum samples enable certain quantitative assays and confirmatory testing that require different collection and processing workflows. Consequently, vendors and laboratory managers who align platform capabilities with specific test portfolios, end-user constraints, and specimen logistics will drive adoption and clinical utility

A nuanced regional perspective on how jurisdictional policy, infrastructure maturity, and supply chain localization shape newborn screening program design and sustainability

Regional dynamics exert pronounced influence on program design, regulatory expectations, and supply chain resilience in newborn screening initiatives. In the Americas, public health programs often emphasize standardized screening panels supported by centralized laboratory networks and a mix of public and private providers, which encourages scale economies and consolidated procurement strategies. Transitional phrases in policy and investment have increased interest in genomic add-ons and pilot programs, but stakeholders must balance expansion with equity and follow-up care capacity.

Meanwhile, Europe, Middle East & Africa present heterogeneous landscapes where regulatory regimes, healthcare financing, and infrastructure maturity vary widely. In well-resourced jurisdictions, advanced analytical platforms and comprehensive confirmatory pathways are increasingly common, whereas resource-limited settings prioritize robust, low-complexity assays and training to expand basic coverage. Cross-border collaborations and capacity-building initiatives play a key role in narrowing gaps and enabling technology transfer.

Across Asia-Pacific, rapid modernization of laboratory networks and strong domestic manufacturing capabilities support accelerating adoption of advanced screening modalities. However, diverse reimbursement models and population health priorities mean that rollout strategies differ, with some economies piloting genomic integration while others focus on optimizing existing biochemical screening. Overall, regional strategy must account for regulatory harmonization, supply chain diversification, and investments in workforce development to ensure sustainable program expansion

A strategic synthesis of competitive behaviors emphasizing interoperability, evidence generation, strategic alliances, and service excellence that drive the newborn screening vendor landscape

Competitive dynamics among industry participants reflect a blend of technological differentiation, strategic partnerships, and emphasis on service and support to meet clinical and laboratory needs. Leading instrument manufacturers focus on enhancing platform interoperability and reducing time-to-result through workflow automation, while reagent suppliers prioritize lot-to-lot consistency and regulatory-compliant documentation to support accreditation requirements. In parallel, laboratory service providers and reference networks concentrate on scaling confirmatory testing capacity and developing standardized care pathways that minimize time to diagnosis and treatment initiation.

Strategic activity also includes partnerships between technology vendors and clinical networks to validate expanded panels, as well as collaborations with academic centers to refine variant interpretation frameworks and evidence generation. Furthermore, companies are directing resources toward training programs and remote support capabilities to reduce technical barriers for decentralized laboratories and to ensure consistent quality across sites. Mergers and alliances continue to shape the supplier landscape, enabling broader product portfolios and distribution reach while creating opportunities for integrated solutions that bundle instruments, consumables, software, and data services.

Collectively, these corporate strategies emphasize reliability, scalability, and regulatory alignment. Organizations that balance innovation with clear pathways for clinical validation and robust post-market support will sustain competitive advantage and foster stronger partnerships with public health programs and healthcare providers

Actionable strategic imperatives for leaders to accelerate adoption, secure supply resilience, and embed quality frameworks that translate screening advances into clinical outcomes

Industry leaders must adopt pragmatic steps to convert technological promise into operational and clinical impact while navigating policy and supply chain complexities. First, invest in interoperable laboratory informatics and standardized reporting formats to ensure that screening results integrate smoothly into electronic health records and population health registries, thereby strengthening follow-up continuity and outcome measurement. Second, prioritize workforce development by funding hands-on training, remote support, and competency assessments so that laboratories and clinicians can reliably implement evolving assays and interpret complex genetic findings.

Next, cultivate diversified supplier relationships and explore regional manufacturing or distribution partnerships to mitigate procurement disruptions and reduce exposure to trade variability. Simultaneously, embed lifecycle management practices that extend equipment uptime and align maintenance schedules with clinical demand patterns. In parallel, engage proactively with regulatory bodies and payers to co-design evidence generation studies that demonstrate clinical utility, real-world performance, and health-economic implications while addressing ethical concerns related to genomic screening.

Finally, pursue collaborative models that link vendors, laboratories, clinicians, and public health entities to pilot integrated care pathways and data-sharing initiatives. By aligning commercial strategy with clinical priorities and system-level goals, leaders can accelerate adoption, preserve diagnostic quality, and deliver measurable improvements in neonatal health outcomes

A transparent, multi-source research methodology combining literature synthesis, expert engagement, and iterative validation to ensure robust and actionable newborn screening insights

The research approach combines systematic secondary literature review, targeted primary engagement with domain experts, and rigorous data triangulation to ensure validity and applicability of insights. Initially, the methodology synthesized peer-reviewed literature, regulatory guidance documents, technical whitepapers, and conference proceedings to map the technology landscape, clinical guidelines, and operational practices. This provided a foundation for identifying key themes and knowledge gaps that warranted further investigation through primary research.

Primary engagement comprised structured interviews with laboratory directors, clinical geneticists, procurement specialists, and public health officials to capture real-world implementation experiences, pain points, and strategic priorities. In addition, vendor discussions explored product roadmaps, validation practices, and service models. Responses were anonymized and cross-checked to avoid bias and to ensure that conclusions reflect consensus where possible and divergent views where appropriate.

Finally, iterative triangulation reconciled qualitative insights with documented evidence, and quality controls included validation of technical descriptions by subject-matter experts and consistency checks across data sources. The methodology emphasized transparency by documenting inclusion and exclusion criteria, interview protocols, and validation steps to support reproducibility and to facilitate informed use of the report's findings

A concise synthesis underscoring the imperative to align technological innovation, operational readiness, and equitable program design to unlock newborn screening benefits

In conclusion, the newborn screening landscape stands at an inflection point where analytical innovation, data integration, and strategic collaboration can materially improve early detection and long-term outcomes for affected infants. Technological advances-from tandem mass spectrometry and high-performance chromatography to targeted molecular assays and broader genomic sequencing-offer complementary capabilities that laboratories and health systems can deploy in layered screening pathways. Yet, realizing clinical benefit depends on operational readiness, regulatory alignment, and equitable access across regions and care settings.

Moving forward, stakeholders must prioritize interoperability, workforce capacity, and evidence-based engagement with regulatory and payer entities to ensure that expanded screening delivers measurable health improvements without compromising quality or exacerbating disparities. Supply chain resilience and procurement agility remain essential as trade dynamics and policy shifts influence access to instruments and consumables. By focusing on pragmatic measures-such as diversified sourcing, lifecycle maintenance, standardized reporting, and collaborative validation-organizations can mitigate risk while advancing programmatic goals.

Ultimately, the combination of clinical need, technological opportunity, and system-level commitment creates a window for meaningful progress in newborn screening. Stakeholders who align strategy with operational execution and patient-centered outcomes will be best positioned to translate innovation into enduring public health impact

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Newborn Screening Market, by Technology

  • 8.1. High Performance Liquid Chromatography
  • 8.2. Immunoassay
  • 8.3. Molecular Techniques
    • 8.3.1. Polymerase Chain Reaction
    • 8.3.2. Sanger Sequencing
  • 8.4. Next Generation Sequencing
  • 8.5. Tandem Mass Spectrometry

9. Newborn Screening Market, by Test Type

  • 9.1. Cystic Fibrosis
  • 9.2. Endocrine Disorders
  • 9.3. Hemoglobin Disorders
  • 9.4. Inborn Errors Of Metabolism

10. Newborn Screening Market, by Sample Type

  • 10.1. Dried Blood Spot
  • 10.2. Serum Sample

11. Newborn Screening Market, by End User

  • 11.1. Diagnostic Laboratories
  • 11.2. Hospitals And Clinics
  • 11.3. Research Laboratories

12. Newborn Screening Market, by Region

  • 12.1. Americas
    • 12.1.1. North America
    • 12.1.2. Latin America
  • 12.2. Europe, Middle East & Africa
    • 12.2.1. Europe
    • 12.2.2. Middle East
    • 12.2.3. Africa
  • 12.3. Asia-Pacific

13. Newborn Screening Market, by Group

  • 13.1. ASEAN
  • 13.2. GCC
  • 13.3. European Union
  • 13.4. BRICS
  • 13.5. G7
  • 13.6. NATO

14. Newborn Screening Market, by Country

  • 14.1. United States
  • 14.2. Canada
  • 14.3. Mexico
  • 14.4. Brazil
  • 14.5. United Kingdom
  • 14.6. Germany
  • 14.7. France
  • 14.8. Russia
  • 14.9. Italy
  • 14.10. Spain
  • 14.11. China
  • 14.12. India
  • 14.13. Japan
  • 14.14. Australia
  • 14.15. South Korea

15. United States Newborn Screening Market

16. China Newborn Screening Market

17. Competitive Landscape

  • 17.1. Market Concentration Analysis, 2025
    • 17.1.1. Concentration Ratio (CR)
    • 17.1.2. Herfindahl Hirschman Index (HHI)
  • 17.2. Recent Developments & Impact Analysis, 2025
  • 17.3. Product Portfolio Analysis, 2025
  • 17.4. Benchmarking Analysis, 2025
  • 17.5. Abbott Laboratories
  • 17.6. Agilent Technologies, Inc.
  • 17.7. Bio-Rad Laboratories, Inc.
  • 17.8. BioMerieux SA
  • 17.9. Danaher Corporation
  • 17.10. MP Biomedicals LLC
  • 17.11. Novartis AG
  • 17.12. PerkinElmer, Inc.
  • 17.13. Shimadzu Corporation
  • 17.14. Siemens Healthineers AG
  • 17.15. Thermo Fisher Scientific Inc.
  • 17.16. Trivitron Healthcare
  • 17.17. Waters Corporation

LIST OF FIGURES

  • FIGURE 1. GLOBAL NEWBORN SCREENING MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL NEWBORN SCREENING MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL NEWBORN SCREENING MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL NEWBORN SCREENING MARKET SIZE, BY TECHNOLOGY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL NEWBORN SCREENING MARKET SIZE, BY TEST TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL NEWBORN SCREENING MARKET SIZE, BY SAMPLE TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL NEWBORN SCREENING MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL NEWBORN SCREENING MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL NEWBORN SCREENING MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL NEWBORN SCREENING MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. UNITED STATES NEWBORN SCREENING MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 12. CHINA NEWBORN SCREENING MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL NEWBORN SCREENING MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL NEWBORN SCREENING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL NEWBORN SCREENING MARKET SIZE, BY HIGH PERFORMANCE LIQUID CHROMATOGRAPHY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL NEWBORN SCREENING MARKET SIZE, BY HIGH PERFORMANCE LIQUID CHROMATOGRAPHY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL NEWBORN SCREENING MARKET SIZE, BY HIGH PERFORMANCE LIQUID CHROMATOGRAPHY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL NEWBORN SCREENING MARKET SIZE, BY IMMUNOASSAY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL NEWBORN SCREENING MARKET SIZE, BY IMMUNOASSAY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL NEWBORN SCREENING MARKET SIZE, BY IMMUNOASSAY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL NEWBORN SCREENING MARKET SIZE, BY MOLECULAR TECHNIQUES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL NEWBORN SCREENING MARKET SIZE, BY MOLECULAR TECHNIQUES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL NEWBORN SCREENING MARKET SIZE, BY MOLECULAR TECHNIQUES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL NEWBORN SCREENING MARKET SIZE, BY MOLECULAR TECHNIQUES, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL NEWBORN SCREENING MARKET SIZE, BY POLYMERASE CHAIN REACTION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL NEWBORN SCREENING MARKET SIZE, BY POLYMERASE CHAIN REACTION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL NEWBORN SCREENING MARKET SIZE, BY POLYMERASE CHAIN REACTION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL NEWBORN SCREENING MARKET SIZE, BY SANGER SEQUENCING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL NEWBORN SCREENING MARKET SIZE, BY SANGER SEQUENCING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL NEWBORN SCREENING MARKET SIZE, BY SANGER SEQUENCING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL NEWBORN SCREENING MARKET SIZE, BY NEXT GENERATION SEQUENCING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL NEWBORN SCREENING MARKET SIZE, BY NEXT GENERATION SEQUENCING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL NEWBORN SCREENING MARKET SIZE, BY NEXT GENERATION SEQUENCING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL NEWBORN SCREENING MARKET SIZE, BY TANDEM MASS SPECTROMETRY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL NEWBORN SCREENING MARKET SIZE, BY TANDEM MASS SPECTROMETRY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL NEWBORN SCREENING MARKET SIZE, BY TANDEM MASS SPECTROMETRY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL NEWBORN SCREENING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL NEWBORN SCREENING MARKET SIZE, BY CYSTIC FIBROSIS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL NEWBORN SCREENING MARKET SIZE, BY CYSTIC FIBROSIS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL NEWBORN SCREENING MARKET SIZE, BY CYSTIC FIBROSIS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL NEWBORN SCREENING MARKET SIZE, BY ENDOCRINE DISORDERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL NEWBORN SCREENING MARKET SIZE, BY ENDOCRINE DISORDERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL NEWBORN SCREENING MARKET SIZE, BY ENDOCRINE DISORDERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL NEWBORN SCREENING MARKET SIZE, BY HEMOGLOBIN DISORDERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL NEWBORN SCREENING MARKET SIZE, BY HEMOGLOBIN DISORDERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL NEWBORN SCREENING MARKET SIZE, BY HEMOGLOBIN DISORDERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL NEWBORN SCREENING MARKET SIZE, BY INBORN ERRORS OF METABOLISM, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL NEWBORN SCREENING MARKET SIZE, BY INBORN ERRORS OF METABOLISM, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL NEWBORN SCREENING MARKET SIZE, BY INBORN ERRORS OF METABOLISM, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL NEWBORN SCREENING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL NEWBORN SCREENING MARKET SIZE, BY DRIED BLOOD SPOT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL NEWBORN SCREENING MARKET SIZE, BY DRIED BLOOD SPOT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL NEWBORN SCREENING MARKET SIZE, BY DRIED BLOOD SPOT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL NEWBORN SCREENING MARKET SIZE, BY SERUM SAMPLE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL NEWBORN SCREENING MARKET SIZE, BY SERUM SAMPLE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL NEWBORN SCREENING MARKET SIZE, BY SERUM SAMPLE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL NEWBORN SCREENING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL NEWBORN SCREENING MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL NEWBORN SCREENING MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL NEWBORN SCREENING MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL NEWBORN SCREENING MARKET SIZE, BY HOSPITALS AND CLINICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL NEWBORN SCREENING MARKET SIZE, BY HOSPITALS AND CLINICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL NEWBORN SCREENING MARKET SIZE, BY HOSPITALS AND CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL NEWBORN SCREENING MARKET SIZE, BY RESEARCH LABORATORIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL NEWBORN SCREENING MARKET SIZE, BY RESEARCH LABORATORIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL NEWBORN SCREENING MARKET SIZE, BY RESEARCH LABORATORIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL NEWBORN SCREENING MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 56. AMERICAS NEWBORN SCREENING MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 57. AMERICAS NEWBORN SCREENING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 58. AMERICAS NEWBORN SCREENING MARKET SIZE, BY MOLECULAR TECHNIQUES, 2018-2032 (USD MILLION)
  • TABLE 59. AMERICAS NEWBORN SCREENING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 60. AMERICAS NEWBORN SCREENING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 61. AMERICAS NEWBORN SCREENING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 62. NORTH AMERICA NEWBORN SCREENING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 63. NORTH AMERICA NEWBORN SCREENING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 64. NORTH AMERICA NEWBORN SCREENING MARKET SIZE, BY MOLECULAR TECHNIQUES, 2018-2032 (USD MILLION)
  • TABLE 65. NORTH AMERICA NEWBORN SCREENING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 66. NORTH AMERICA NEWBORN SCREENING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 67. NORTH AMERICA NEWBORN SCREENING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 68. LATIN AMERICA NEWBORN SCREENING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 69. LATIN AMERICA NEWBORN SCREENING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 70. LATIN AMERICA NEWBORN SCREENING MARKET SIZE, BY MOLECULAR TECHNIQUES, 2018-2032 (USD MILLION)
  • TABLE 71. LATIN AMERICA NEWBORN SCREENING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 72. LATIN AMERICA NEWBORN SCREENING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 73. LATIN AMERICA NEWBORN SCREENING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 74. EUROPE, MIDDLE EAST & AFRICA NEWBORN SCREENING MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 75. EUROPE, MIDDLE EAST & AFRICA NEWBORN SCREENING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 76. EUROPE, MIDDLE EAST & AFRICA NEWBORN SCREENING MARKET SIZE, BY MOLECULAR TECHNIQUES, 2018-2032 (USD MILLION)
  • TABLE 77. EUROPE, MIDDLE EAST & AFRICA NEWBORN SCREENING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 78. EUROPE, MIDDLE EAST & AFRICA NEWBORN SCREENING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 79. EUROPE, MIDDLE EAST & AFRICA NEWBORN SCREENING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 80. EUROPE NEWBORN SCREENING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 81. EUROPE NEWBORN SCREENING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 82. EUROPE NEWBORN SCREENING MARKET SIZE, BY MOLECULAR TECHNIQUES, 2018-2032 (USD MILLION)
  • TABLE 83. EUROPE NEWBORN SCREENING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 84. EUROPE NEWBORN SCREENING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 85. EUROPE NEWBORN SCREENING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 86. MIDDLE EAST NEWBORN SCREENING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 87. MIDDLE EAST NEWBORN SCREENING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 88. MIDDLE EAST NEWBORN SCREENING MARKET SIZE, BY MOLECULAR TECHNIQUES, 2018-2032 (USD MILLION)
  • TABLE 89. MIDDLE EAST NEWBORN SCREENING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 90. MIDDLE EAST NEWBORN SCREENING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 91. MIDDLE EAST NEWBORN SCREENING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 92. AFRICA NEWBORN SCREENING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 93. AFRICA NEWBORN SCREENING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 94. AFRICA NEWBORN SCREENING MARKET SIZE, BY MOLECULAR TECHNIQUES, 2018-2032 (USD MILLION)
  • TABLE 95. AFRICA NEWBORN SCREENING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 96. AFRICA NEWBORN SCREENING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 97. AFRICA NEWBORN SCREENING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 98. ASIA-PACIFIC NEWBORN SCREENING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 99. ASIA-PACIFIC NEWBORN SCREENING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 100. ASIA-PACIFIC NEWBORN SCREENING MARKET SIZE, BY MOLECULAR TECHNIQUES, 2018-2032 (USD MILLION)
  • TABLE 101. ASIA-PACIFIC NEWBORN SCREENING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 102. ASIA-PACIFIC NEWBORN SCREENING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 103. ASIA-PACIFIC NEWBORN SCREENING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 104. GLOBAL NEWBORN SCREENING MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 105. ASEAN NEWBORN SCREENING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 106. ASEAN NEWBORN SCREENING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 107. ASEAN NEWBORN SCREENING MARKET SIZE, BY MOLECULAR TECHNIQUES, 2018-2032 (USD MILLION)
  • TABLE 108. ASEAN NEWBORN SCREENING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 109. ASEAN NEWBORN SCREENING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 110. ASEAN NEWBORN SCREENING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 111. GCC NEWBORN SCREENING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 112. GCC NEWBORN SCREENING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 113. GCC NEWBORN SCREENING MARKET SIZE, BY MOLECULAR TECHNIQUES, 2018-2032 (USD MILLION)
  • TABLE 114. GCC NEWBORN SCREENING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 115. GCC NEWBORN SCREENING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 116. GCC NEWBORN SCREENING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 117. EUROPEAN UNION NEWBORN SCREENING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 118. EUROPEAN UNION NEWBORN SCREENING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 119. EUROPEAN UNION NEWBORN SCREENING MARKET SIZE, BY MOLECULAR TECHNIQUES, 2018-2032 (USD MILLION)
  • TABLE 120. EUROPEAN UNION NEWBORN SCREENING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 121. EUROPEAN UNION NEWBORN SCREENING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 122. EUROPEAN UNION NEWBORN SCREENING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 123. BRICS NEWBORN SCREENING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 124. BRICS NEWBORN SCREENING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 125. BRICS NEWBORN SCREENING MARKET SIZE, BY MOLECULAR TECHNIQUES, 2018-2032 (USD MILLION)
  • TABLE 126. BRICS NEWBORN SCREENING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 127. BRICS NEWBORN SCREENING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 128. BRICS NEWBORN SCREENING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 129. G7 NEWBORN SCREENING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 130. G7 NEWBORN SCREENING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 131. G7 NEWBORN SCREENING MARKET SIZE, BY MOLECULAR TECHNIQUES, 2018-2032 (USD MILLION)
  • TABLE 132. G7 NEWBORN SCREENING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 133. G7 NEWBORN SCREENING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 134. G7 NEWBORN SCREENING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 135. NATO NEWBORN SCREENING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 136. NATO NEWBORN SCREENING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 137. NATO NEWBORN SCREENING MARKET SIZE, BY MOLECULAR TECHNIQUES, 2018-2032 (USD MILLION)
  • TABLE 138. NATO NEWBORN SCREENING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 139. NATO NEWBORN SCREENING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 140. NATO NEWBORN SCREENING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 141. GLOBAL NEWBORN SCREENING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 142. UNITED STATES NEWBORN SCREENING MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 143. UNITED STATES NEWBORN SCREENING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 144. UNITED STATES NEWBORN SCREENING MARKET SIZE, BY MOLECULAR TECHNIQUES, 2018-2032 (USD MILLION)
  • TABLE 145. UNITED STATES NEWBORN SCREENING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 146. UNITED STATES NEWBORN SCREENING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 147. UNITED STATES NEWBORN SCREENING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 148. CHINA NEWBORN SCREENING MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 149. CHINA NEWBORN SCREENING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 150. CHINA NEWBORN SCREENING MARKET SIZE, BY MOLECULAR TECHNIQUES, 2018-2032 (USD MILLION)
  • TABLE 151. CHINA NEWBORN SCREENING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 152. CHINA NEWBORN SCREENING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 153. CHINA NEWBORN SCREENING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)